Logo image of BLFS

BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis

NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD

26.67  -0.84 (-3.05%)

After market: 26.4 -0.27 (-1.01%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BLFS. BLFS was compared to 56 industry peers in the Life Sciences Tools & Services industry. While BLFS seems to be doing ok healthwise, there are quite some concerns on its profitability. BLFS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BLFS had negative earnings in the past year.
In the past year BLFS had a positive cash flow from operations.
BLFS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
BLFS Yearly Net Income VS EBIT VS OCF VS FCFBLFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -12.06%, BLFS perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
With a decent Return On Equity value of -14.14%, BLFS is doing good in the industry, outperforming 64.91% of the companies in the same industry.
Industry RankSector Rank
ROA -12.06%
ROE -14.14%
ROIC N/A
ROA(3y)-16.25%
ROA(5y)-9.96%
ROE(3y)-19.97%
ROE(5y)-12.59%
ROIC(3y)N/A
ROIC(5y)N/A
BLFS Yearly ROA, ROE, ROICBLFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 46.15%, BLFS is in line with its industry, outperforming 49.12% of the companies in the same industry.
BLFS's Gross Margin has declined in the last couple of years.
BLFS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.95%
GM growth 5Y-13.79%
BLFS Yearly Profit, Operating, Gross MarginsBLFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100

More info and screens

4

2. Health

2.1 Basic Checks

BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLFS has been increased compared to 1 year ago.
The number of shares outstanding for BLFS has been increased compared to 5 years ago.
BLFS has a worse debt/assets ratio than last year.
BLFS Yearly Shares OutstandingBLFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BLFS Yearly Total Debt VS Total AssetsBLFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 12.17 indicates that BLFS is not in any danger for bankruptcy at the moment.
BLFS's Altman-Z score of 12.17 is amongst the best of the industry. BLFS outperforms 98.25% of its industry peers.
BLFS has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BLFS (0.03) is better than 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 12.17
ROIC/WACCN/A
WACC11.41%
BLFS Yearly LT Debt VS Equity VS FCFBLFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

BLFS has a Current Ratio of 2.78. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BLFS (2.78) is comparable to the rest of the industry.
A Quick Ratio of 1.78 indicates that BLFS should not have too much problems paying its short term obligations.
BLFS has a Quick ratio of 1.78. This is comparable to the rest of the industry: BLFS outperforms 42.11% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 1.78
BLFS Yearly Current Assets VS Current LiabilitesBLFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.50% over the past year.
Looking at the last year, BLFS shows a very negative growth in Revenue. The Revenue has decreased by -23.51% in the last year.
BLFS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 48.71% yearly.
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
Revenue 1Y (TTM)-23.51%
Revenue growth 3Y43.88%
Revenue growth 5Y48.71%
Sales Q2Q%-8.27%

3.2 Future

The Earnings Per Share is expected to grow by 27.22% on average over the next years. This is a very strong growth
BLFS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.52% yearly.
EPS Next Y29.49%
EPS Next 2Y34.84%
EPS Next 3Y27.22%
EPS Next 5YN/A
Revenue Next Year-25.59%
Revenue Next 2Y-18.29%
Revenue Next 3Y-5.15%
Revenue Next 5Y7.52%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BLFS Yearly Revenue VS EstimatesBLFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
BLFS Yearly EPS VS EstimatesBLFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BLFS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BLFS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLFS Price Earnings VS Forward Price EarningsBLFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLFS Per share dataBLFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

BLFS's earnings are expected to grow with 27.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.84%
EPS Next 3Y27.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BLFS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOLIFE SOLUTIONS INC

NASDAQ:BLFS (2/21/2025, 8:03:44 PM)

After market: 26.4 -0.27 (-1.01%)

26.67

-0.84 (-3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners102.53%
Inst Owner Change-92.14%
Ins Owners1.69%
Ins Owner Change-0.45%
Market Cap1.23B
Analysts83.75
Price Target31.52 (18.19%)
Short Float %7.21%
Short Ratio12.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-95.8%
Min EPS beat(2)-246.6%
Max EPS beat(2)55%
EPS beat(4)3
Avg EPS beat(4)-39.55%
Min EPS beat(4)-246.6%
Max EPS beat(4)55%
EPS beat(8)4
Avg EPS beat(8)-96.78%
EPS beat(12)6
Avg EPS beat(12)-68.09%
EPS beat(16)8
Avg EPS beat(16)-59.05%
Revenue beat(2)2
Avg Revenue beat(2)16.67%
Min Revenue beat(2)15.98%
Max Revenue beat(2)17.36%
Revenue beat(4)3
Avg Revenue beat(4)12.26%
Min Revenue beat(4)-3.92%
Max Revenue beat(4)19.6%
Revenue beat(8)4
Avg Revenue beat(8)2.83%
Revenue beat(12)6
Avg Revenue beat(12)1.18%
Revenue beat(16)10
Avg Revenue beat(16)2.49%
PT rev (1m)2.32%
PT rev (3m)3.69%
EPS NQ rev (1m)33.5%
EPS NQ rev (3m)-4.25%
EPS NY rev (1m)9.66%
EPS NY rev (3m)-43.24%
Revenue NQ rev (1m)-5.39%
Revenue NQ rev (3m)-9.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.39
P/FCF N/A
P/OCF 135.26
P/B 3.78
P/tB 14.95
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)0.2
OCFY0.74%
SpS2.57
BVpS7.05
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.06%
ROE -14.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.15%
FCFM N/A
ROA(3y)-16.25%
ROA(5y)-9.96%
ROE(3y)-19.97%
ROE(5y)-12.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.95%
GM growth 5Y-13.79%
F-Score6
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.45%
Cap/Sales 16.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 1.78
Altman-Z 12.17
F-Score6
WACC11.41%
ROIC/WACCN/A
Cap/Depr(3y)96.88%
Cap/Depr(5y)114.83%
Cap/Sales(3y)9.61%
Cap/Sales(5y)10.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.67%
EPS Next Y29.49%
EPS Next 2Y34.84%
EPS Next 3Y27.22%
EPS Next 5YN/A
Revenue 1Y (TTM)-23.51%
Revenue growth 3Y43.88%
Revenue growth 5Y48.71%
Sales Q2Q%-8.27%
Revenue Next Year-25.59%
Revenue Next 2Y-18.29%
Revenue Next 3Y-5.15%
Revenue Next 5Y7.52%
EBIT growth 1Y58.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year122.81%
EBIT Next 3Y36.92%
EBIT Next 5YN/A
FCF growth 1Y61.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y153.14%
OCF growth 3YN/A
OCF growth 5YN/A